SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma informs about press release

29 Nov 2016 Evaluate

Natco Pharma has informed about a Press Release dated November 29, 2016, titled ‘Natco receives Final Approval for Generic Armodafinil Tablets for USA Market’.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

1158.85 -15.15 (-1.29%)
11-May-2026 10:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1875.00
Dr. Reddys Lab 1284.30
Cipla 1334.20
Zydus Lifesciences 938.00
Lupin 2251.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×